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Heparin free dialysis: comparative data and results in high risk
patients. Heparin free hemodialysis was compared to systemic heparin-
ization, intermittent saline flushes and constant saline infusions in eight,
stable chronic patients dialyzing on hollow—fiber artificial kidneys
(HFAK) at blood flows of 250 to 300 mI/mm. No significant differences
in small molecule clearance, fluid removal or dialyzer clotting were
noted. Since this data showed that heparin free hemodialysis without
supplemental saline was feasible in a group of stable, chronic dialysis
patients, we then prospectively studied twenty—nine patients judged to
be at increased risk of hemorrhage from hepannization during 100
heparin—free dialyses. The incidences of severe and moderate dialyzer
clotting were 7% and 20%, respectively. Seventeen of 27 treatments in
which moderate or severe clotting occurred had identifiable factors
thought to predispose to dialyzer clotting such as low blood flows, poor
vascular—access function, severe hypotension and intradialytic blood
transfusions. Although higher hematocrit values were associated with
greater degrees of dialyser clotting, stepwise discriminant analysis
employing blood flow, blood pressure, hematocrit and transfusion
administration could not develop an accurate predictor or combination
of predictors of clotting. No patient experienced de novo or increased
bleeding and problems with inadequate dialysis were not observed.
Since this method of heparin free dialysis is as safe and effective as
previously reported strategies and requires no specialized equipment or
procedures, it is a reasonable initial strategy for dialyzing high risk
patients.
Strategies for hemodialyzing patients judged to be at in-
creased risk of bleeding during systemic anticoagulation include
low—dose systemic heparinization [1, 2], regional heparinization
[1, 3], regional citrate anticoagulation [4], systemic epopros-
tenol administration [5], development of membrane materials of
low thrombogenicity [61, and anticoagulant free hemodialysis
with [7—12] or without [13, 14] intermittent saline flushes. In this
study we compare four different anticoagulation strategies in a
controlled fashion in eight, stable chronic—hemodialysis pa-
tients and report the results of 100 consecutive dialysis—treat-
ments without systemic heparinization or saline flushes, per-
formed on 29 patients judged to be at increased risk of bleeding
complications.
Methods
For the controlled study of four different anticoagulation
strategies, eight volunteers were solicited from a group of 18
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patients receiving chronic hemodialysis at Albert Einstein Med-
ical Center. Patients receiving anti-platelet or anti-coagulant
drugs were excluded. Each patient was dialyzed once with each
of four anticoagulation strategies on four consecutive—midweek
dialyses.
The first anticoagulation strategy utilized intermittent boluses
of heparin at doses previously determined in each patient to be
adequate to sustain a full treatment with negligible fiber clot-
ting. Total heparin doses ranged from 4000 to 5000 units per
treatment. In the second strategy no supplemental heparin or
saline were given during dialysis. In the third strategy a bolus of
200 cc of 0.9% saline was infused into the arterial line every 30
minutes. In the fourth strategy a constant infusion of 0.9%
saline was run into the arterial line at a rate of 400 cc/hr
throughout the entire treatment. The heparinized saline solution
used to prime the extracorporeal circuit prior to dialysis was
infused into the patients at the start of dialysis. This resulted in
patients receiving up to 500 units of heparin at the beginning of
dialysis.
Prior to each dialysis, 10 minutes into dialysis and at the end
of the treatment the activated clotting time (ACT) was deter-
mined with an ACTester (TRI Med, Inc., Huntington Beach,
California, USA). Other determinations made at the start of
dialysis included patient weight, BUN and serum creatinine.
When peak blood flow was reached (usually 15 to 20 minutes
after initiation of dialysis) and at the end of the treatment
dialyzer urea and creatinine clearances were measured. The
rinse back procedure was effected with 150 to 200 cc of 0.9%
saline. The arterial and venous lines were then clamped and cut
at the blood ports of the artificial kidney. Residual fiber—bundle
volume was then measured by a manual method using a
hand—squeezed air pump to express fluid from the kidney and a
graduated cylinder to measure the fluid volume evacuated. The
percent fiber loss was calculated using the manufacturer's
specifications for the fiber bundle volume of a fresh kidney.
In the prospective study of patients judged at increased risk
of bleeding, 100 consecutive heparin—free dialyses in 29 patients
were performed over a three month period. Data reviewed
included the reason for heparin free dialysis, artificial kidney
type, hematocrit, peak blood flow, intra-dialytic blood transfu-
sions and pre- and post-dialyzer pressures.
A severe clotting episode was defined as clotting necessitat-
ing termination of the treatment or replacement of the artificial
kidney. Mild clotting was defined as up to 25% fiber loss and
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Table 1. Comparative data on four anticoagulation strategies
Heparin
bolus
Heparin
free
Saline
flushes
Saline
infusion
ACTsecPre 135±5 130±7 142±6 143±5
@ 15 mm 195 iia 136 13 137 8 143 8
Post 182±8 107±4 114±6 118±9
Weight loss lbs 4.8 0,6 4.7 0.7 5.5 0.8 5.6 0.9
%predicted 113 23 87 4 127 23 94 26
ABUNmg% 40±4 40±4 43±3 41±4
Creatinine mg% 4.9 0.4 5.0 0.4 4.8 0.5 4.9 0.7
Cur mI/mm—start 149 7 159 5 165 5 167 6
Crça mI/mm—end 146 7 154 7 159 9 162 5
CUrea ml/min—i —3 —5 —6 —5
CCr mI/mm—start 115 6 123 5 125 7 124 4
Ccrml/mjn'—end 108 10 124 9 118 5 114 5
Ccr ml/min—L —7 + 1 —7 —10
% Fiber loss 3 1 5 1 10 5 20 11
Clotting severe 0 0 0 0
Clotting moderate 0 0 1 2
Abbreviations are: ACT, activated clotting time; i, Change; Crea,
dialyzer urea clearance; Ccr, dialyzer creatinine clearance.
a P < 0.05
moderate clotting as greater than 25% fiber loss. Fiber loss was
measured directly in the controlled study and visually estimated
in the prospective study of heparin free dialysis.
Mean values are expressed as the standard error of the
mean. Statistical methods utilized include paired and unpaired
1-tests and stepwise discriminant analysis with values of P less
than 0.05 considered significant. The SPSS-X statistical soft-
ware package was used on the University of Georgia network
computer.
Results
Controlled study
The eight volunteers included four males and four females
who had been on chronic hemodialysis for three to 101 months.
The mean hematocrit was 23 0.9%. Seven patients dialyzed
on cuprophan HFAK (Travenol CF-151 1) and one dialyzed on
a cellulate HFAK (Cordis Dow C-DAK-4000). Treatment times
ranged from 3 to 3-'/2 hours. No patient was transfused during
the course of the study. All patients could attain and tolerate
blood flows of 250 to 300 mI/mm in the extracorporeal circuit.
The remainder of the data is summarized in Table 1. Only the
heparin bolus group had a significant rise in ACT during the
course of dialysis. All groups showed a tendency toward
shorter ACT's at the end of the treatment than at 15 minutes,
but this tendency did not reach statistical significance. The four
groups did not differ significantly with regard to weight loss,
changes in BUN and serum creatinine, or changes in dialyzer
urea or creatinine clearance. There was a tendency toward
larger, fiber—bundle volume losses in the saline groups which
did not achieve significance. There were no instances of severe
clotting with any of the strategies. Three patients in the two
saline groups had episodes of moderate clotting (36 to 69% fiber
loss). No provocative factors for these three episodes (2 Cordis
Dow, I Travenol) could be identified. Significant reductions in
urea or creatinjne clearances or in fluid removal did not occur
and intradialytic increases in transdialyzer pressure gradients of
more than 30 mm Hg did not occur (data not shown).
Prospective study of heparin free dialysis
The 100 treatments were performed on 29 patients (17 males,
12 females). Six patients had acute renal failure, six were
chronic renal failure patients starting hemodialysis and 17 were
long—term hemodialysis patients. Indications for heparin free
dialysis included recent surgery, renal biopsy, pericarditis,
gastrointestinal bleeding, gross hematuria, retinal hemorrhage,
unexplained coma, respiratory failure with mechanical ventila-
tion and recent insertion of subclavian or femoral dialysis
catheters. Thirty—six treatments were with Travenol HFAK's
and 64 with Cordis Dow HFAK's. The mean hematocrit was
higher than in the controlled study (26.2 2.3% vs. 23.0
0.9%, P < 0.01). Twenty of 29 patients could consistently attain
and tolerate blood flows as high as 250 to 300 mllmin. Packed
red blood cells were transfused during 19 dialyses. Twenty
moderate clotting episodes occurred in 14 patients (12 Cordis
Dow, 8 Travenol). Three were associated with severe hypoten-
sion, four with blood flows less than 250 mI/mm, four with blood
transfusion and nine with no obvious precipitating factor. In
only five of 20 moderate clotting episodes were increases in
transdialyzer pressure greater than 30 mm Hg observed. Al-
though systematic data on dialyzer function was not obtained
on these patients, complications related to inadequate control
of azotemia, hyperkalemia or fluid overload were not noted.
Seven severe clotting episodes occurred in five patients (4
Cordis Dow, 3 Travenol). Two of these episodes were associ-
ated with thrombosis and high venous resistances in subclavian
catheters, two with inability to attain blood flows greater than
200 mI/mm, one with blood transfusion, one with severe hypo-
tension and one with no apparent precipitating factor. Severe
clotting episodes occurred from 60 to 195 minutes after initia-
tion of dialysis (mean, 112 17 mm).
In only two of the episodes of severe clotting was the entire
blood volume (247 to 273 ml) in the extracorporeal circuit lost.
In the other five episodes most of the blood in the extra-
corporeal circuit was given back to the patient during reinfu-
sion, which was done in the usual fashion with a saline infusion.
None of the 29 patients developed accelerated or de novo
bleeding complications.
Stepwise discriminant analysis was employed to determine if
blood flow, systolic or diastolic blood pressure, hematocrit or
intradialytic blood transfusions could accurately predict
dialyzer clotting. In one analysis three outcome measures were
used: minimal clotting, moderate clotting and severe clotting. In
the other analysis two outcome measures were used: minimal
clotting and more than minimal clotting. This data is summa-
rized in Table 2. In analysis 1 only hematocnt approached
significance (P = 0.10) by the Wilks' Lambda statistic. In
analysis 2 the P value of hematocrit was significant at 0.04, but
because of the high degree of overlap in hematocrit values
between groups this discriminant function could at best predict
only 72% of the clotting outcomes correctly. No variable other
than hematocrit approached significance by the Wilks' Lambda
statistic.
Discussion
The need for anticoagulation during extracorporeal dialysis of
blood and the occurrence of bleeding problems when heparin-
ization was employed were documented in the early days of
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artificial organ development. The early work of Kolif demon-
strated that dialysis employing the rotating drum dialyzer with
its cellophane membrane required systemic heparinization and
that bleeding from surgical cutdown sites on blood vessels was
a complication of the procedure [15]. Early studies of hol-
low—fiber artificial kidneys (HFAK) suggested that systemic
heparinization was required for dialysis with HFAK and that
even with systemic heparinization clotting of the dialyzer was a
major problem which could limit the usefulness of HFAK
dialysis in many patients with renal failure [16, 17]. Most
dialysis centers continue to observe a high degree of variability
in the heparin requirement of patients dialyzing on HFAK and
some have devised complex heparin modeling—procedures for
determining the optimum heparin dosing—schedule for hemodi-
alysis [181.
Standard systemic heparinization for hemodialysis has been
associated with bleeding complications in up to 26% of treat-
ments in patients with acute renal failure [3]. Table 3 summa-
rizes the findings of several studies designed to use methods
other than standard systemic heparinization in the hemodialysis
of patients judged at high risk for bleeding complications. It
should be noted that these studies often differ significantly from
each other with regard to the types of patients studied, the
definitions of various degrees of clotting and the assessment of
bleeding complications. The technical complexities of regional
heparinization (two precisely controlled infusions of heparin
and protamine) [1, 3] and the improved results with low—dose
systemic hepannization [1, 2] have resulted in the latter tech-
nique becoming the method of choice in most dialysis centers.
Platelet inhibition with epoprostenol has been shown to be an
effective strategy but is associated with flushing, hypotension
and gastrointestinal complaints and requires a precisely—cali-
brated infusion pump for administration [5]. Regional citrate
anticoagulation requires a calcium free dialysate and precise
calibration of two infusion pumps for citrate and calcium, and
carries risks of hypernatremia, hypo- or hypercalcemia, volume
overload and acid base disorders [4]. New membrane materials
such as ethylene—vinyl alcohol co-polymer (ExVal dialyzer)
may offer a direct and simple approach to anti-coagulant free
hemodialysis, although optimal results with this membrane
appear to require double vascular access (separate needles for
arterial and venous flow), a one hour priming of the dialyzer
with heparinized saline and administration of this priming
solution containing approximately 1700 units of heparin to the
patient at the beginning of the dialysis [6].
Several reports have verified the feasibility of heparin free
hemodialysis using intermittent saline boluses (100 to 300
minutes [7—12]. Both cuprophan and cellulosic dialyzers have
been used with blood flows kept in the range of 280 to 300
mI/mm whenever possible. Two studies of blood coagulation
with saline flush dialysis have shown that allowing anticoagul-
ant free blood to come in contact with the potentially
thrombogenic surface of the HFAK membrane does not result
in coagulation profiles suggestive of consumption coagulopathy
[10, 12].
Mechanisms by which saline flushes might exert an anti-
thrombotic effect have not been defined. It is possible that high
blood flows combined with saline flushes might prevent the
buildup of serum proteins, platelets and leukocytes which is
thought to initiate the thrombotic process on dialyzer surfaces.
Table 2. Relationship of selected parameters to dialyzer clotting
Clotting QB SBP DBP HCT Tx%
Analysis I
Minimal (N=73) 261 3 114 3 67 2 25 0.06 21
Moderate
(N=20) 262 5 116 5 69 2 27 1.2 15
Severe (N=7) 254 14 114 11 68 5 28 1.9 14
Pa 0.69 0.98 0.76 0.10 0.77
Analysis 2
Minimal (N=73) 261 3 114 3 67 2 25 0.6 21
Moderate/severe
(N=27) 259 5 115 5 69 2 27 1.0 15
P 0.70 0.89 0.48 0.04 0.47
Abbreviations are: QB, blood flow, mi/mm; SBP, lowest systolic
blood pressure; DBP, lowest diastolic blood pressure; HCT, hemato-
crit, volumes %; Tx%, % of treatments in which blood transfused.
a Wilks Lambda
The results of saline flush dialysis are superior to low-dose
systemic heparinization with regard to bleeding complications.
The only drawbacks to saline flush dialysis are increased
nursing time, the cost of the supplemental saline and the need to
adjust ultrafiltration rates for removal of the supplemental
saline.
Heparin free dialysis without saline flushes has been reported
to be successful with both coil and hollow fiber dialyzers of
standard membrane material [13, 14]. Raja et al [14] reported 20
such heparin free dialyses with cellulate HFAK's in 14 stable,
chronic hemodialysis patients. No severe clotting episodes
occurred and the mean fiber bundle volume loss was 18%. Raja
also emphasized the importance of high blood flow rates in
preventing clotting with 10 of 14 patients being dialyzed at flows
of 300 mI/mm.
Since the mechanism by which saline flushes might exert an
anti-thrombotic effect has not been conclusively established
and since successful heparin—free dialysis without saline flushes
has been reported, our controlled study of anticoagulation was
undertaken to determine if dialyzer function and clotting with
heparin free, saline free dialysis were significantly different
from the results of dialysis with systemic heparin, saline flushes
or saline infusion.
Although the amount of heparin given to the heparin group
and its modest prolongation of the ACT would be categorized as
low dose heparinization, the minimal fiber loss, predictable fluid
removal and maintenance of good, small molecule clearance
indicate that effective dialysis was achieved. Similarly accept-
able levels of dialyzer function and clotting were observed with
the heparin free, saline flush and saline infusion strategies. This
study of a small group of patients with relatively low hemato-
crits, dialyzed at high blood flows for relatively short treatment
times suggests that there may be a sizable subgroup of patients
with renal failure in whom dialysis without heparin or saline
flushes is feasible and equivalent in efficacy to other, more
complicated regimens. It remains to be established, however,
whether a similar comparative study in patients having a higher
clotting tendency (higher hematocrits, poor blood flows, vascu-
lar instability, intradialytic transfusions, etc.) might reveal
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Table 3. Results of various techniques for dialyzing high risk patients
Reference Technique
No. of
patients
No. of
dialyses
Dialyzer clotting .
Bleeding
complicationsmoderate severe
[31 Regional heparin 23 29 7% 28% 24%
[1] Low dose heparin
Regional heparin
59
59
133
122
5%
3%
0
0
10%
19%
[2] Low dose heparin 51 300 6% 0 5%
[4] Regional citrate 4 15 0 0 0
[12] Saline flushes 9 12 0 0 0
[9] Saline flushes 29 111 18% 10% 0
1111 Saline flushes 28 156 6% 5% 0
16] ExVal dialyzer 21 87 0 0 0
[5] Epoprostenol 28 77 — 6% 3%
differences in efficacy among the four anticoagulation strate-
gies.
The prospective study of 100 heparin free, saline free dialyses
provided both a much larger and a more diverse group of
patients than did the controlled study. Severe clotting occurred
in 7% of dialyses and moderate clotting occurred in 20%. No
patients suffered de novo or accelerated bleeding complica-
tions. These results are similar to those of saline flush dialysis.
Moderate dialyzer clotting did not lead to noticeable prob-
lems with inadequate dialysis or fluid removal in our study or in
previously reported studies [10, 14]. This may be the result of
increased blood flow through the unclotted fibers or alterna-
tively may suggest that such clotting occurs late in dialysis after
most of the fluid and solute removal has already been achieved.
We feel that the higher incidence of dialyzer fiber loss in the
prospective study as compared to the controlled study is at least
partially attributable to differences between the patient groups
since six of seven episodes of severe clotting and 11 of 20
episodes of moderate clotting occurred in association with
putative risk factors for clotting (inadequate blood flows, im-
paired vascular—access function, severe hypotension and blood
transfusions) which were not present in any of the patients in
the controlled study. In addition, the mean hematocrit of the
patients in the prospective study was higher than that of the
patients in the controlled study. Increases in hematocrit have
been shown to shorten the bleeding time in uremia, an effect
which has been atributed to increased platelet interaction with
vascular surfaces [19, 20]. Although the conventional wisdom in
the dialysis community is that dialyzer clotting is more common
in patients with higher hematocrits, this hypothesis has not, to
our knowledge, been verified experimentally.
Stepwise discriminant analysis was performed on the data
obtained in the prospective study to determine if a risk profile
for dialyzer clotting could be developed. Although the patients
exhibiting moderate or severe dialyzer clotting had a signifi-
cantly higher hematocnt than those who did not, the amount of
overlap in the hematocrit values greatly restricted the predic-
tive value of this variable. The other variables tested including
peak blood flows, nadir blood pressures and transfusion admin-
istration were similarly of poor predictive value. A larger study
designed to provide a wider range of values for the variables in
question might be more useful in the development of a clotting
risk profile.
Our study suggests that heparin free dialysis without saline
flushes is a safe, simple and effective therapeutic strategy in
patients judged at high risk for complications of anticoagula-
tion. We propose that heparin free dialysis with high blood
flows and without saline flushes should be the first strategy
employed in the dialysis of patients at high risk of bleeding with
more complicated strategies being reserved for patients in
whom this regimen fails.
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